TipRanks
Immunic (DE:10V)
FRANKFURT:10V
Germany Market
10V
Immunic
RESEARCH TOOLSreports

Immunic (10V) Stock News & Sentiment

4 Followers
Unchanged $56 Target as Slutsky Reiterates Buy on IMUX, Highlighting Vidofludimus Calcium’s Dual Mechanism and Safety Advantage in MS
Premium
Ratings
Unchanged $56 Target as Slutsky Reiterates Buy on IMUX, Highlighting Vidofludimus Calcium’s Dual Mechanism and Safety Advantage in MS
27d ago
IMUX
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
Premium
Company Announcements
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
29d ago
8K
IMUX
Analyst Reiterates Buy on Immunic, Sees Undervalued MS Opportunity with Unchanged $56 Price Target
Premium
Ratings
Analyst Reiterates Buy on Immunic, Sees Undervalued MS Opportunity with Unchanged $56 Price Target
1M ago
IMUX
Immunic: Buy Rating Reiterated as Analyst Highlights Multiple Sclerosis Milestones and Maintains $22 Price Target
Premium
Ratings
Immunic: Buy Rating Reiterated as Analyst Highlights Multiple Sclerosis Milestones and Maintains $22 Price Target
2M ago
IMUX
Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline
Premium
Ratings
Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline
2M ago
IMUX
Immunic Adds Veteran Finance Leader to Board
Premium
Company Announcements
Immunic Adds Veteran Finance Leader to Board
2M ago
8K
IMUX
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
Premium
TipRanks Newswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
2M ago
IMUX
QNTM
More DE:10V News >

10V News on the Web

Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks News
Bullish
Analyst Reiterates Buy on Immunic, Sees Undervalued MS Opportunity with Unchanged $56 Price Target
TipRanks News
Bullish
Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline
TipRanks News
Bullish
Is Immunic Inc (IMUX) Struggling After Recent Earnings? EPS Misses Estimates with GF Score: 32/100
GuruFocus News
Bearish
Immunic Adds Veteran Finance Leader to Board
TipRanks News
Neutral
Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans
TipRanks News
Neutral
Immunic Names CEO Erik Lundgren to Board
TipRanks News
Neutral
Immunic Expands Equity Plan and Reelects Board Directors
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
DE:10V
Sector Average
Media Buzz
This Week1 articles
Weekly Average1.5 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:10V’s Media Buzz Sentiment?
1 articles about DE:10V were published this week. In an average week, 1.5 articles are published.
    What is DE:10V’s weekly average amount of articles?
    In an average week, 1.5 articles about DE:10V are published.
      What is DE:10V’s News Sentiment?
      100% of articles about DE:10V were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        XENEXenon
        ABTAbbott Laboratories
        BBIOBridgeBio Pharma
        BDXBecton Dickinson
        NVSNovartis
        Showing the stocks with the most bullish news sentiment over the past week